REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock - Currency: USD
Overall REGN gets a fundamental rating of 7 out of 10. We evaluated REGN against 555 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. A decent growth rate in combination with a cheap valuation! Better keep an eye on REGN. These ratings could make REGN a good candidate for value investing.
1. Profitability
1.1 Basic Checks
REGN had positive earnings in the past year.
REGN had a positive operating cash flow in the past year.
Each year in the past 5 years REGN has been profitable.
Each year in the past 5 years REGN had a positive operating cash flow.
1.2 Ratios
The Return On Assets of REGN (11.98%) is better than 95.32% of its industry peers.
REGN has a better Return On Equity (15.31%) than 95.50% of its industry peers.
The Return On Invested Capital of REGN (9.45%) is better than 94.95% of its industry peers.
REGN had an Average Return On Invested Capital over the past 3 years of 12.18%. This is below the industry average of 14.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.98% | ||
| ROE | 15.31% | ||
| ROIC | 9.45% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.18%
ROIC(5y)17.79%
1.3 Margins
REGN has a better Profit Margin (31.94%) than 97.12% of its industry peers.
REGN's Profit Margin has improved in the last couple of years.
The Operating Margin of REGN (28.85%) is better than 97.48% of its industry peers.
In the last couple of years the Operating Margin of REGN has remained more or less at the same level.
REGN has a Gross Margin of 86.69%. This is amongst the best in the industry. REGN outperforms 89.73% of its industry peers.
In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.85% | ||
| PM (TTM) | 31.94% | ||
| GM | 86.69% |
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), REGN is creating some value.
REGN has about the same amout of shares outstanding than it did 1 year ago.
REGN has less shares outstanding than it did 5 years ago.
The debt/assets ratio for REGN has been reduced compared to a year ago.
2.2 Solvency
REGN has an Altman-Z score of 6.52. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
REGN has a Altman-Z score of 6.52. This is amongst the best in the industry. REGN outperforms 81.08% of its industry peers.
The Debt to FCF ratio of REGN is 0.91, which is an excellent value as it means it would take REGN, only 0.91 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.91, REGN belongs to the best of the industry, outperforming 95.32% of the companies in the same industry.
REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.09, REGN is doing worse than 64.68% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.91 | ||
| Altman-Z | 6.52 |
ROIC/WACC1.1
WACC8.59%
2.3 Liquidity
A Current Ratio of 4.93 indicates that REGN has no problem at all paying its short term obligations.
REGN's Current ratio of 4.93 is in line compared to the rest of the industry. REGN outperforms 52.43% of its industry peers.
REGN has a Quick Ratio of 4.03. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN has a Quick ratio (4.03) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.03 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.47% over the past year.
The Earnings Per Share has been growing by 13.12% on average over the past years. This is quite good.
The Revenue has been growing slightly by 7.52% in the past year.
Measured over the past years, REGN shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)2.47%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-13.93%
Revenue 1Y (TTM)7.52%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%-3.69%
3.2 Future
The Earnings Per Share is expected to grow by 5.56% on average over the next years.
Based on estimates for the next years, REGN will show a small growth in Revenue. The Revenue will grow by 4.44% on average per year.
EPS Next Y-20.5%
EPS Next 2Y-5.79%
EPS Next 3Y2.73%
EPS Next 5Y5.56%
Revenue Next Year-5.35%
Revenue Next 2Y0.53%
Revenue Next 3Y3.82%
Revenue Next 5Y4.44%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.77, the valuation of REGN can be described as very reasonable.
REGN's Price/Earnings ratio is rather cheap when compared to the industry. REGN is cheaper than 96.22% of the companies in the same industry.
REGN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.98.
Based on the Price/Forward Earnings ratio of 12.87, the valuation of REGN can be described as correct.
Based on the Price/Forward Earnings ratio, REGN is valued cheaply inside the industry as 94.59% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.49, REGN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.77 | ||
| Fwd PE | 12.87 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaper than 97.12% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, REGN is valued cheaply inside the industry as 94.41% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.01 | ||
| EV/EBITDA | 9.95 |
4.3 Compensation for Growth
The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.9
EPS Next 2Y-5.79%
EPS Next 3Y2.73%
5. Dividend
5.1 Amount
With a yearly dividend of 0.68%, REGN is not a good candidate for dividend investing.
REGN's Dividend Yield is rather good when compared to the industry average which is at 96.38. REGN pays more dividend than 98.38% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.42, REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
5.2 History
REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-5.79%
EPS Next 3Y2.73%
NASDAQ:REGN (6/30/2025, 2:54:23 PM)
521.48
+0.48 (+0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.08%
Inst Owner Change0.47%
Ins Owners1.86%
Ins Owner Change0%
Market Cap56.30B
Analysts80.59
Price Target750.26 (43.87%)
Short Float %2.59%
Short Ratio1.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-8.66%
Max EPS beat(2)4.93%
EPS beat(4)3
Avg EPS beat(4)1.88%
Min EPS beat(4)-8.66%
Max EPS beat(4)6.79%
EPS beat(8)6
Avg EPS beat(8)2.08%
EPS beat(12)10
Avg EPS beat(12)5.54%
EPS beat(16)13
Avg EPS beat(16)9.63%
Revenue beat(2)0
Avg Revenue beat(2)-5.11%
Min Revenue beat(2)-9.31%
Max Revenue beat(2)-0.91%
Revenue beat(4)1
Avg Revenue beat(4)-1.98%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)2.93%
Revenue beat(8)4
Avg Revenue beat(8)-0.63%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)12
Avg Revenue beat(16)4.32%
PT rev (1m)-8.99%
PT rev (3m)-21.23%
EPS NQ rev (1m)0.47%
EPS NQ rev (3m)-19.37%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-16.27%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)-8.42%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-8.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.77 | ||
| Fwd PE | 12.87 | ||
| P/S | 4 | ||
| P/FCF | 19.01 | ||
| P/OCF | 14.24 | ||
| P/B | 1.92 | ||
| P/tB | 2 | ||
| EV/EBITDA | 9.95 |
EPS(TTM)44.31
EY8.5%
EPS(NY)40.51
Fwd EY7.77%
FCF(TTM)27.43
FCFY5.26%
OCF(TTM)36.61
OCFY7.02%
SpS130.46
BVpS272.18
TBVpS261.37
PEG (NY)N/A
PEG (5Y)0.9
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.98% | ||
| ROE | 15.31% | ||
| ROCE | 11.96% | ||
| ROIC | 9.45% | ||
| ROICexc | 12.53% | ||
| ROICexgc | 13.12% | ||
| OM | 28.85% | ||
| PM (TTM) | 31.94% | ||
| GM | 86.69% | ||
| FCFM | 21.03% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.18%
ROIC(5y)17.79%
ROICexc(3y)40.56%
ROICexc(5y)38.47%
ROICexgc(3y)47.83%
ROICexgc(5y)42.84%
ROCE(3y)15.42%
ROCE(5y)22.52%
ROICexcg growth 3Y-3.25%
ROICexcg growth 5Y17.1%
ROICexc growth 3Y-7.38%
ROICexc growth 5Y14.08%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.91 | ||
| Debt/EBITDA | 0.59 | ||
| Cap/Depr | 199.98% | ||
| Cap/Sales | 7.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 86.71% | ||
| Profit Quality | 65.83% | ||
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.03 | ||
| Altman-Z | 6.52 |
F-Score5
WACC8.59%
ROIC/WACC1.1
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.77%
Profit Quality(5y)77.84%
High Growth Momentum
Growth
EPS 1Y (TTM)2.47%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-13.93%
EPS Next Y-20.5%
EPS Next 2Y-5.79%
EPS Next 3Y2.73%
EPS Next 5Y5.56%
Revenue 1Y (TTM)7.52%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%-3.69%
Revenue Next Year-5.35%
Revenue Next 2Y0.53%
Revenue Next 3Y3.82%
Revenue Next 5Y4.44%
EBIT growth 1Y-0.68%
EBIT growth 3Y-22.17%
EBIT growth 5Y13.8%
EBIT Next Year-16.54%
EBIT Next 3Y6.1%
EBIT Next 5Y6.01%
FCF growth 1Y17.22%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-7.66%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%